Clinical Drug Experience Knowledgebase

Criteria

Inclusion Criteria:

Male and/or female subjects aged 16 to 35 years
Subjects presenting with mild to moderate acne (stage 2 or stage 3 with at least 12 inflammatory lesions on face according to the Global Acne Evaluation)

Female subjects of child-bearing potential who:

use the same reliable hormonal contraceptive method (oral contraceptive, implant, intra-uterine device, patch, cervical cap, vaginal ring and injection) for at least 3 months prior to study inclusion and throughout the study or
use a reliable non-hormonal contraceptive method (copper intra-uterine device, condoms, diaphragm, cervical cap and spermicide) for at least 1 month prior to study inclusion and throughout the study or
have no sexual intercourse and agreeing not to have any throughout the study or
are surgically sterile (oophorectomy, hysterectomy or tubal ligation),
Subjects and/or all legal representatives (for minor subjects) who have given written informed consent
Subjects who are willing to comply with the study requirements
Subjects with Social Security (health insurance) coverage (according to the French requirements)

Exclusion Criteria:

Subjects with any systemic disorder or face dermatoses other than acne that would in any way confound interpretation of the study results (e.g. atopic dermatitis, eczema, or psoriasis)
Subjects with a condition or receiving a medication and/or with a history of medical/surgical events which, in the opinion of the Investigator, could compromise the safety of the subject or affect the outcome of the study
Subjects with a history of skin cancer
Female subjects who are pregnant (positive urine pregnancy test) or lactating or who are planning to become pregnant during the study
Subjects who have started, stopped or changed of hormonal treatment (contraception, thyroid …) in the 3 months prior the study inclusion
Subjects with hypersensitivity to the active substances of Epiduo (Adapalene and/or benzoyl peroxide) or to one of its excipients
Subjects who are sensitive to peroxides (oxygenated water)
Subjects who have received isotretinoin treatment in the 6 months prior to study inclusion
Subjects who have been exposed to excessive UV light (natural or artificial) in the 1 month prior to the study inclusion or having planned excessive UV light exposure during the study (e.g. ski holidays, holidays in the tropics…)
Subjects who have used systemic drugs for more than 3 consecutive days related to antibiotics, anti-inflammatory, corticoids, anti-acneic in the 4 weeks prior to study inclusion
Subjects who have used topical drugs for more than 3 consecutive days related to antibiotics, anti-inflammatory, corticoids, anti-acneic in the 2 weeks prior to study inclusion
Subjects who have used scrub, anti-seborrheic topical cosmetic products and/or who have applied self-tanning products on face in the 1 week prior the study inclusion
Subjects who have applied cosmetic products for more than 5 consecutive days with alpha hydroxyl-acids, vitamin C, hyaluronic acids in the 1 week prior the study inclusion
Subjects having washed the face and/or the hair the day of the study inclusion (only water is accepted the morning of the study inclusion)
Subjects having applied any topical products on face (including make-up) the day of the study inclusion
Subjects who have planned a major surgery during the study requiring hospitalization under general anesthesia and the use of systemic or topical drugs (e.g. antibiotics, anti-inflammatory) for more than 1 week
Subjects who declare to be deprived of their freedom by administrative or legal decision or who are under guardianship
Subjects who cannot be contacted by telephone in case of emergency
Subjects belonging to the staff of the study centre
Subjects in an exclusion period or participating in another biomedical research study